GILD

Gilead Sciences
D

GILD

Arincen87/100B
166.870
USD
-0.73
(-0.44%)
Pre Open·168.040USD+1.170(+0.70%)
Last updated: · Delayed 15 min

Gilead Sciences net income 1990–2026

Gilead Sciences earned 2.43B USD in Q3 FY2026, the three months to 30 September 2026, down 20.4% on the same quarter a year before. Gilead Sciences's net income over the last twelve months was -3.86B USD, down 147.6% on the twelve months before. In fiscal year 2025 it earned 8.51B USD, up 1,672.9% on the year before.

Last updated 9 Nov 2026 · Next report 9 Feb 2027

Net income

Net income · -7.3% a year over 10 yearsNet margin

Growth

Fiscal yearPeriod endingNet incomeGrowthNet marginRevenue
TTM30 Sept 2026-3.86B-147.63%-12.47%30.99B
FY202531 Dec 20258.51B+1,672.92%28.90%29.44B
FY202431 Dec 2024480.00M-91.53%1.67%28.75B
FY202331 Dec 20235.67B+23.37%20.89%27.12B
FY202231 Dec 20224.59B-26.23%16.83%27.28B
FY202131 Dec 20216.23B+4,960.98%22.80%27.31B
FY202031 Dec 2020123.00M-97.72%0.50%24.69B
FY201931 Dec 20195.39B-1.26%23.99%22.45B
FY201831 Dec 20185.46B+17.87%24.65%22.13B
FY201731 Dec 20174.63B-65.72%17.73%26.11B
FY201631 Dec 201613.50B-25.44%44.43%30.39B
FY201531 Dec 201518.11B+49.64%55.48%32.64B
FY201431 Dec 201412.10B+293.53%48.62%24.89B
FY201331 Dec 20133.08B+18.63%27.45%11.20B
FY201231 Dec 20122.59B-7.55%26.72%9.70B
FY201131 Dec 20112.80B-3.36%33.43%8.39B
FY201031 Dec 20102.90B+10.07%36.50%7.95B
FY200931 Dec 20092.64B+33.19%37.59%7.01B
FY200831 Dec 20081.98B+22.51%37.09%5.34B
FY200731 Dec 20071.62B—38.19%4.23B
FY200631 Dec 2006-1.19B-246.20%-39.32%3.03B
FY200531 Dec 2005813.91M+81.12%40.13%2.03B
FY200431 Dec 2004449.37M—33.92%1.32B
FY200331 Dec 2003-72.00M-199.87%-8.30%867.86M
FY200231 Dec 200272.10M+37.93%15.45%466.79M
FY200131 Dec 200152.27M—22.36%233.77M
FY200031 Dec 2000-56.78M—-29.03%195.56M
FY199931 Dec 1999-66.50M—-39.35%169.00M
FY199831 Dec 1998-44.80M—-29.65%151.10M
FY199731 Dec 1997-72.90M—-55.10%132.30M
FY199631 Dec 1996-21.70M—-64.97%33.40M
FY199531 Dec 1995-27.40M—-1,014.81%2.70M
FY199431 Dec 1994-31.30M—-638.78%4.90M
FY199231 Dec 1992-14.10M—-335.71%4.20M
FY199131 Dec 1991-4.50M—-160.71%2.80M
FY199031 Dec 1990-4.00M—-307.69%1.30M

Figures in USD. Shares and EPS are adjusted for stock splits. Quarterly growth is on the same quarter a year before; TTM is the last four quarters.

See also:Revenue,EPS,Shares outstanding,Operating income,Cash on hand,Total debt,Free cash flow,Stock buybacks,Income statement

Common questions about Gilead Sciences's profit

Source: Financial Modeling Prep

Risk Disclosure: Trading in financial instruments involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Never invest money you cannot afford to lose, and carefully assess the suitability of complex products such as CFDs and derivatives in light of your financial situation. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Arincen would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes.

Arincen and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Arincen and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Arincen may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

© 2026 - Arincen L.L.C-FZ - License No. 2420098.01. All Rights Reserved.